Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Theliatinib |
Synonyms | |
Therapy Description |
Theliatinib (HMPL 309) is a selective, ATP-competitive Egfr inhibitor that demonstrates anti-tumor activity in animal models (PMID: 28881608). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Theliatinib | HMPL-309|HMPL309|HMPL 309|Xiliertinib | EGFR Inhibitor (Pan) 61 | Theliatinib (HMPL 309) is a selective, ATP-competitive Egfr inhibitor that demonstrates anti-tumor activity in animal models (PMID: 28881608). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|